CSL Behring Completes Licensing Deal with uniQure for Hemophilia Gene Therapy
CSL Behring completed the previously announced commercialization and license agreement with uniQure for a gene therapy candidate targeting hemophilia B.
The novel gene therapy, etranacogene dezaparvovec (AMT-061), for the treatment of hemophilia B is currently in Phase 3 clinical trials and has been shown to result in near-normal levels of Factor IX (FIX), the blood-clotting protein lacking in people with hemophilia B.
The acquisition complements both CSL Behring’s cell and gene therapy scientific platform and its hematology product portfolio, which include other treatments for hemophilia B as well as therapies for treating hemophilia A, von Willebrand disease, thrombosis, and other life-threatening conditions
